MedTrace Logo

BEACON Suicide Prevention in Men Study

NCT03473535 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2023-09-13

No results posted yet for this study

Summary

The purpose of this study is to evaluate the use of problem-solving therapy (PST), supplemented by a smartphone application, in the treatment of men who present to the Emergency Departments in Ontario. A total of 100 men in 5 Emergency Departments will be enrolled and randomized to receive either face-to-face PST or face-to-face PST supplemented by the BEACON Suicide Prevention smartphone application. Face-to-face therapy may be provided via videoconference to accommodate patient preference and ongoing pandemic restrictions. Participants will complete six sessions of PST and outcomes will be measured at baseline, 6 weeks, two post-therapy follow-up time points (3 and 6 months). Participants will also be asked to complete a qualitative interview about their participation in the study and their experience with the smartphone application.

Conditions

  • Intentional Self-Harm
  • Suicide

Interventions

COMBINATION_PRODUCT

BEACON + Problem Solving Therapy

Six sessions of face-to-face PST delivered by a trained Research Therapist and access to the BEACON Suicide Prevention smartphone application.

BEHAVIORAL

Problem-Solving Therapy

Six sessions of face-to-face PST delivered by a trained Research Therapist.

Sponsors & Collaborators

  • Ottawa Hospital Research Institute

    collaborator OTHER

  • University of Ottawa

    lead OTHER

Principal Investigators

  • Simon Hatcher, PhD · University of Ottawa

  • Marnin Heisel, PhD · Western University, Canada

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-31
Primary Completion
2023-03-31
Completion
2024-09-23

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03473535 on ClinicalTrials.gov